Vaxart, Inc.
For the period ended Aug 6, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 6, 2026 · Filed Aug 6, 2026
Use the contents to explore the available documents and sections.
VXRT$0.550.0%Stored close · as of Jul 8, 2026
Contents
EX-99.1 · COVID-19 Program Update
COVID-19 Program Update
| ● | In July 2026, Vaxart announced topline data from the 400-participant sentinel safety cohort of its Phase 2b clinical trial evaluating the Company’s oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator. The primary endpoint in the sentinel cohort was safety, and key findings include: |
| o | No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher AEs were reported in either the oral pill vaccine or mRNA arms of the trial. |
| o | The most common AEs reported in participants receiving the oral pill vaccine were malaise/fatigue and headache, while participants receiving the mRNA vaccine reported injection site pain and tenderness, malaise/fatigue, headache, and myalgia/muscle pain as the most common AEs. |
| ● | The Company expects to release topline efficacy and safety data from the complete study, comprising the 400 participants in the sentinel safety cohort and approximately 5,000 participants in the main cohort, in the first half of 2027. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.